Novartis Forecasts 2025-2030 Sales CAGR Of +5-6% CC

Reuters11-20

Nov 20 (Reuters) - NOVARTIS AG ::
*PROJECTS +5-6% CC SALES CAGR 2025-2030, WITH LONG-TERM GROWTH BACKED BY 30+ POTENTIAL HIGH-VALUE PIPELINE ASSETS
*PEAK SALES GUIDANCE UPGRADED FOR KISQALI AND SCEMBLIX; NOVARTIS NOW HAS EIGHT DE-RISKED, IN-MARKET ASSETS WITH USD 3-10 BILLION PEAK SALES POTENTIAL
*15+ POTENTIALLY SUBMISSION-ENABLING READOUTS EXPECTED IN NEXT TWO YEARS TO FUEL LONG-TERM GROWTH
*PIPELINE INCLUDES 30+ POTENTIAL HIGH-VALUE MEDICINES, WITH 10+ LICENSED OR ACQUIRED IN PAST TWO YEARS
*OUTLOOK: EXPECTS TO RETURN TO 40%+ MARGINS BY 2029
*PLANNED ACQUISITION OF AVIDITY BIOSCIENCES IS EXPECTED TO CLOSE IN FIRST HALF OF 2026
*SALES GUIDANCE FOR KISQALI RAISED FROM USD 8 BILLION+ TO USD 10 BILLION+
*SALE GUIDANCE FOR SCEMBLIX RAISED FROM USD 3 BILLION+ TO USD 4 BILLION+

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 20-NOV-202506:00:00.09 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584077129?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 14:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584077129","market":"fut","top_or_hot":-1,"title":"Novartis Forecasts 2025-2030 Sales CAGR Of +5-6% CC","media":"Reuters","content":"<html><body>Nov 20 (Reuters) - NOVARTIS AG <novn.s>::<br/>*PROJECTS +5-6% CC SALES CAGR 2025-2030, WITH LONG-TERM GROWTH BACKED BY 30+ POTENTIAL HIGH-VALUE PIPELINE ASSETS<br/>*PEAK SALES GUIDANCE UPGRADED FOR KISQALI AND SCEMBLIX; NOVARTIS NOW HAS EIGHT DE-RISKED, IN-MARKET ASSETS WITH USD 3-10 BILLION PEAK SALES POTENTIAL<br/>*15+ POTENTIALLY SUBMISSION-ENABLING READOUTS EXPECTED IN NEXT TWO YEARS TO FUEL LONG-TERM GROWTH<br/>*PIPELINE INCLUDES 30+ POTENTIAL HIGH-VALUE MEDICINES, WITH 10+ LICENSED OR ACQUIRED IN PAST TWO YEARS<br/>*OUTLOOK: EXPECTS TO RETURN TO 40%+ MARGINS BY 2029<br/>*PLANNED ACQUISITION OF AVIDITY BIOSCIENCES IS EXPECTED TO CLOSE IN FIRST HALF OF 2026<br/>*SALES GUIDANCE FOR KISQALI RAISED FROM USD 8 BILLION+ TO USD 10 BILLION+<br/>*SALE GUIDANCE FOR SCEMBLIX RAISED FROM USD 3 BILLION+ TO USD 4 BILLION+<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 20-NOV-202506:00:00.09 GMT</novn.s></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Forecasts 2025-2030 Sales CAGR Of +5-6% CC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Forecasts 2025-2030 Sales CAGR Of +5-6% CC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-20 14:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>Nov 20 (Reuters) - NOVARTIS AG <novn.s>::<br/>*PROJECTS +5-6% CC SALES CAGR 2025-2030, WITH LONG-TERM GROWTH BACKED BY 30+ POTENTIAL HIGH-VALUE PIPELINE ASSETS<br/>*PEAK SALES GUIDANCE UPGRADED FOR KISQALI AND SCEMBLIX; NOVARTIS NOW HAS EIGHT DE-RISKED, IN-MARKET ASSETS WITH USD 3-10 BILLION PEAK SALES POTENTIAL<br/>*15+ POTENTIALLY SUBMISSION-ENABLING READOUTS EXPECTED IN NEXT TWO YEARS TO FUEL LONG-TERM GROWTH<br/>*PIPELINE INCLUDES 30+ POTENTIAL HIGH-VALUE MEDICINES, WITH 10+ LICENSED OR ACQUIRED IN PAST TWO YEARS<br/>*OUTLOOK: EXPECTS TO RETURN TO 40%+ MARGINS BY 2029<br/>*PLANNED ACQUISITION OF AVIDITY BIOSCIENCES IS EXPECTED TO CLOSE IN FIRST HALF OF 2026<br/>*SALES GUIDANCE FOR KISQALI RAISED FROM USD 8 BILLION+ TO USD 10 BILLION+<br/>*SALE GUIDANCE FOR SCEMBLIX RAISED FROM USD 3 BILLION+ TO USD 4 BILLION+<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 20-NOV-202506:00:00.09 GMT</novn.s></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nRSD4lCd25:1","article_id":"2584077129","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584077129","pubTimestamp":1763619366,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nov 20 (Reuters) - NOVARTIS AG ::*PROJECTS +5-6% CC SALES CAGR 2025-2030, WITH LONG-TERM GROWTH BACKED BY 30+ POTENTIAL HIGH-VALUE PIPELINE ASSETS*PEAK SALES GUIDANCE UPGRADED FOR KISQALI AND SCEMBLIX","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技","RNA":"Avidity Biosciences, Inc.","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4588":"碎股"},"translate_title":"诺华预测2025-2030年销售额复合年增长率为+5-6%CC","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":0.9},"content_text":"Nov 20 (Reuters) - NOVARTIS AG ::*PROJECTS +5-6% CC SALES CAGR 2025-2030, WITH LONG-TERM GROWTH BACKED BY 30+ POTENTIAL HIGH-VALUE PIPELINE ASSETS*PEAK SALES GUIDANCE UPGRADED FOR KISQALI AND SCEMBLIX; NOVARTIS NOW HAS EIGHT DE-RISKED, IN-MARKET ASSETS WITH USD 3-10 BILLION PEAK SALES POTENTIAL*15+ POTENTIALLY SUBMISSION-ENABLING READOUTS EXPECTED IN NEXT TWO YEARS TO FUEL LONG-TERM GROWTH*PIPELINE INCLUDES 30+ POTENTIAL HIGH-VALUE MEDICINES, WITH 10+ LICENSED OR ACQUIRED IN PAST TWO YEARS*OUTLOOK: EXPECTS TO RETURN TO 40%+ MARGINS BY 2029*PLANNED ACQUISITION OF AVIDITY BIOSCIENCES IS EXPECTED TO CLOSE IN FIRST HALF OF 2026*SALES GUIDANCE FOR KISQALI RAISED FROM USD 8 BILLION+ TO USD 10 BILLION+*SALE GUIDANCE FOR SCEMBLIX RAISED FROM USD 3 BILLION+ TO USD 4 BILLION+  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 20-NOV-202506:00:00.09 GMT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584077129","isCrawlerRequest":true}